Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia

Publication Date

2019

Journal Title

J Pharm Pract

Abstract

© The Author(s) 2019. Sacubitril/valsartan (Entresto®) is the first commercially available angiotensin receptor neprilysin inhibitor (ARNI) approved for use in heart failure patients with a reduced ejection fraction. It is a combination drug that contains sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. Our report outlines a case of probable ARNI-induced hyponatremia occurring in an elderly woman with heart failure with a reduced ejection fraction. According to Naranjo Adverse Drug Reaction Assessment, score indicated a likely association between patient’s hyponatremia and her use of sacubitril/valsartan.

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Cardiology

PMID

30776953

DOI

10.1177/0897190019828915

Full Text for Zucker SOM at Hofstra/Northwell
For the public and Northwell Health campuses

Share

COinS